Eidos Therapeutics to Host Conference Call and Webcast to Discuss Phase 2 Clinical Trial Results
Eidos Therapeutics to Host Conference Call and Webcast to Discuss Phase 2 Clinical Trial Results
October 29, 2018 at 8:00 AM EDT
The conference call will include a presentation followed by a Q&A session and will be accessible through an audio webcast at ir.eidostx.com. An archived replay of the webcast will be available on the company's website for 90 days following the live presentation.
The conference call can be accessed in a listen-only mode as follows: +1-844-293-0174 (U.S. toll free) or +1-916-582-3546 (international), conference ID 8594856.
About AG10
AG10 is an investigational, orally administered small molecule designed to potently stabilize tetrameric transthyretin, or TTR, thereby halting at its outset the series of molecular events that give rise to amyloidosis, or ATTR. AG10 is currently being examined in a Phase 2 clinical trial in patients with ATTR cardiomyopathy and symptomatic heart failure. Results from this trial will be presented on
AG10 was designed to mimic a naturally-occurring variant of the TTR gene (T119M) that is considered a “rescue mutation” because it has been shown to prevent ATTR in individuals also carrying a pathogenic, or disease-causing, mutation in the other copy of their TTR gene. To our knowledge, AG10 is the only TTR stabilizer in development that has been observed to mimic the “super-stabilizing” properties of this rescue mutation.
About
Media Contact:
619-849-5382
Carolyn@canalecomm.com
Investor Contact:
Burns McClellan
212-213-0006
agray@burnsmc.com
Source: Eidos Therapeutics, Inc.